GeneCentric Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2024
GeneCentric Therapeutics , a company making precision medicine more precise through RNA-based diagnostics, today announced upcoming presentations at the American Association for Cancer Research Annual Meeting 2024 being held in San Diego, California from April 5-10.
- GeneCentric Therapeutics , a company making precision medicine more precise through RNA-based diagnostics, today announced upcoming presentations at the American Association for Cancer Research Annual Meeting 2024 being held in San Diego, California from April 5-10.
- Presentations will include a poster describing a new colorectal cancer predictive response signature (MSS-PRS) that selects tumors not identified with conventional MSI testing but have molecular characteristics consistent with microsatellite instability, making them a potential target for immune checkpoint inhibition.
- A second poster presentation describes ongoing clinical validation for PurISTSM, a novel RNA-expression test developed in collaboration with Tempus.
- Details of the AACR presentations are as follows:
Session: PO.CL01.01 – Diagnostic Biomarkers 1, Section 42
The posters will be accessible under the News & Events section of the Company’s website following the conference.